EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CVAC: Curevac N.V.

23 Oct 25 14:23
LAST:

5.405

CHANGE:
 0.02		OPEN:
5.370		HIGH:
5.410		ASK:
0.000		VOLUME:
177.2K
CHG(%):
0.28		PREV:
5.390		LOW:
5.370		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Oct 255.3705.4105.3705.405177.2K
22 Oct 255.3705.4005.3705.390354.2K
21 Oct 255.3405.3805.3405.370418.7K
20 Oct 255.3605.3705.3505.360444.8K
17 Oct 255.3705.3805.3405.360514.9K
16 Oct 255.4005.4105.3405.370648.2K
15 Oct 255.3705.4055.3705.400355.0K
14 Oct 255.3605.3805.3505.360434.6K
13 Oct 255.3705.4005.3605.390383.9K
10 Oct 255.4205.4205.3505.380449.1K

COMPANY PROFILE

Name:Curevac N.V.
About:CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Sector:Healthcare
Industry:Biotechnology
Address:Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076
Website:https://www.curevac.com
CIK:0001809122
ISIN:NL0015436031
FIGI:BBG00W9LXXJ4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:5.37 
Forward P/E:-12.32 
EPS Ratio:1.01 
Price to Book:2.08 
Price to Sales:2.40 
EBITDA:248.67M 
Shares:225.17M 
Market Cap:1.217B 

TECHNICAL INDICATORS

MA5:5.380.5%
MA10:5.380.5%
MA20:5.390.3%
MA50:5.390.3%
MA100:5.351.0%
MA200:4.4122.6%
STO9:100.00 
STO14:62.50
RSI14:42.86
WPR14:-28.57
ATR:0.04 
Week High:5.410.1%
Week Low:5.341.2%
Month High:5.450.8%
Month Low:5.3322.6%
Year High:5.725.8%
Year Low:2.37128.1%
Volatility:3.19